ACADIA Pharma (ACAD) Stock
Fundamentals
Latest news
About ACADIA Pharma
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Catherine E. Owen Adams | CEO & Director | 1970 |
| Mr. Mark C. Schneyer | Executive VP & CFO | 1974 |
| Ms. Jennifer J. Rhodes J.D. | Executive VP, Chief Legal Officer & Secretary | 1970 |
| Dr. Elizabeth H. Z. Thompson Ph.D. | Executive VP and Head of Research & Development | 1976 |
| Mr. Thomas Andrew Garner | Executive VP & Chief Commercial Officer | 1976 |
| Mr. Scott Cenci | Senior VP, Chief Information & Data Officer | — |
| Mr. Albert S. Kildani | Senior Vice President of Investor Relations & Corporate Communications | — |
| Mr. Carl Segerstrom | Chief People Officer | — |
| Mr. James K. Kihara | Senior Vice President of Finance | 1981 |
| Ms. Allyson McMillan-Youngblood | Senior Vice President of Rare Disease Franchise | — |



